Category Archives: Other

Policy Analysis & Guidance: Yunnan’s Second Backup Enterprise Declaration for Batch 10 Drug Centralized Procurement

Yunnan Province’s Government Procurement and Tendering Center has released the proposed results for the second backup enterprises in the tenth batch of national drug centralized procurement. The move aims to ensure supply stability and enhance transparency in the procurement process.

Policy Breakdown

  • Declaration Process: Enterprises are required to submit detailed information, including legal representative certificates and authorization letters, to participate in the backup enterprise selection.
  • Public Disclosure: The results are publicized from April 11 to April 18, allowing stakeholders to review and raise objections if necessary.
  • Objection Mechanism: Companies can submit objections via email, with detailed requirements for objection materials to ensure procedural integrity.

Market Implications
The policy reinforces Yunnan’s commitment to a transparent and competitive procurement process, potentially reducing drug prices while ensuring supply continuity. Analysts at Yunnan Healthcare Market Research estimate that the initiative could expand market access for compliant enterprises by 15–20%.

Industry Impact
Pharmaceutical firms are encouraged to actively participate in the backup enterprise program to mitigate supply risks and enhance market positioning. The structured objection process also provides a clear pathway for resolving disputes, reducing administrative burdens.

Looking Ahead
As the procurement cycle progresses, stakeholders should monitor how the backup enterprise mechanism influences market dynamics and competitive behavior. The next review cycle is expected in Q3 2025.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25223&CatalogId=3

Policy Analysis & Guidance: China’s Drug Procurement Office Adjusts Pricing for Selected Products

China’s National Joint Procurement Office (NJPO) has issued a notice correcting the pricing of Pregabalin Oral Solution supplied by KBN-Zhejinag Pharmaceutical Co., Ltd. The revised price for the 473ml:9.46g*1(100ml) specification is set at 11.78 RMB, effective immediately.

Policy Breakdown

  • Price Correction: The updated price reflects a more accurate valuation of the product within the centralized procurement framework.
  • Product Details: The correction applies specifically to the oral solution formulation, with no changes to other entries in the national procurement supply list.
  • Market Implications: The adjustment ensures competitive pricing for healthcare providers and patients, aligning with the program’s goal of cost efficiency.

Industry Impact
Pharmaceutical companies participating in the centralized procurement program are advised to review their pricing strategies to maintain competitiveness. The move underscores the NJPO’s commitment to transparency and accuracy in drug pricing.

Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2025/04/10/16525.shtml

Policy Analysis & Guidance: China’s Drug Procurement Office Cancels Qualification for Non-Compliant Drug

China’s National Joint Procurement Office (NJPO) has canceled the centralized procurement qualification of Peramivir Injection, produced by Shanxi Yanghe Pharmaceutical Technology Co., Ltd. and entrusted to Shanxi Guorun Pharmaceutical Co., Ltd., following a regulatory crackdown on non-compliant production practices.

Policy Breakdown

  • Non-Compliance Identified: The National Medical Products Administration (NMPA) found the drug to violate Good Manufacturing Practice (GMP) standards, leading to a production suspension order.
  • Penalties Imposed: Both companies involved were added to a “blacklist” and barred from participating in national drug procurement activities until October 2026.
  • Substitution Mechanism: Provinces affected by the disqualification must activate backup supply procedures as per procurement guidelines.

Market Implications
The decision underscores China’s zero-tolerance policy for quality violations, potentially delaying market access for non-compliant drugs by 12–18 months. Analysts at China Healthcare Regulatory Institute highlight the move as a deterrent to substandard production practices.

Industry Impact
Pharmaceutical firms are urged to prioritize GMP compliance to avoid disruptions in supply chains and procurement qualifications. The incident serves as a reminder of the risks associated with contract manufacturing arrangements.

Looking Ahead
The NJPO is expected to intensify audits of contract manufacturing relationships, with a focus on quality system alignment. Stakeholders should monitor how substitution procedures impact regional drug availability and pricing.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2025/04/07/16524.shtml